SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMMUNE NETWORK RESEARCH (VSE:IMM)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: pete meyer who wrote (56)5/8/1998 10:01:00 PM
From: burner  Read Replies (1) of 134
 
Immune Network Research Ltd -

Second 1F7 mAb study in progress

Immune Network Research Ltd IMMShares issued 199704521998-05-07 close $0.08Friday May 8 1998Mr. Victor Jones reports At the request of the VSE the company reports that the study of its proprietary monoclonal antibody 1F7 in infected macaque monkeys as a model of IIIV disease is in progress and there are no material changes in the company. The study now involves nine macaques, seven of which are infected with SIIIV 89.6P and is on day 31 of a protocol which continues into October with blood and tissue samples being taken and cryogenically preserved for later analysis. The study, announced April 14, is evaluating the effectiveness of 1F7 mAb as an adjuvant of therapeutic for human infection related to the AIDS virus and the macaques have received a series of five injections of mAB 1F7. This research is financed under a partnership between the company and Immpheron Inc. of Lexington, KY, to continue research and development following earlier promising findings in the effectiveness of mAb 1F7. The encouraging results of the company's previous study leading to this live animal study on mAb 1F7 were published in the prestigious "Proceedings of the National Academy of Science USA" (PNAS Vol. 95 pp. 276-281, Jan. 6, 1998). In that study, mAb 1F7 injection increased the breadth and potency of virus neutralizing antibodies in all three monkeys chronically infected with SHIV-IIIB. No such changes occurred in a SIIV-IIIB infected monkey with an isotype control antibody.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News